Current understanding of the mechanisms of action of hormonal therapies in carcinomas of the breast, prostate, endometrium and ovary is briefly reviewed. The range of available hormonal therapies for each disease is considered together with response rates, toxicity and any evidence for survival benefit. Practical guidelines for the palliative use of hormonal therapies are suggested.
Huggins C., Hodges CVStudies on prostatic cancer. The effects of castration, of oestrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate . Cancer Res1941; 1: 293-97.
2.
Rose C., Mouridsen HTEndocrine management of advanced breast cancer. Horm Res1989; 32 (suppl 1): 189-87.
3.
Hamm JT, Allegra JCNew hormonal approaches to the treatment of breast cancer. Critical Rev Oncol/Haematol, 1991; 11: 29-41.
4.
Henderson IC, Harris JR, Kinne DW, Hellman S.Cancer of the breast. In: DeVita VT Jr, Hellman H, Rosenberg SA eds. Cancer: principles and practice of oncology, third edition. Philadelphia: JB Lippincott, 1989. 1197-1268.
5.
Howell A., Dodwell DJ, Anderson H.New endocrine approaches to breast cancer. In: Bailliere's Clin Endocrinol Metab1990; 4: 67-84.
6.
Donegan WLCancer of the breast in men. CanCancer J Clin1991; 41: 339-54.
7.
Bratherton DG , Brown CH, Buchanan R. et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer1984; 50: 199-205.
8.
Early Breast Cancer Trialist's Collaborative Group.Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet1992; 339: 71-85.
9.
Rubens RDManagement of early breast cancer. Br Med J1992; 304: 1361-64.
10.
Formander T. , Rutqvist LE, Cedermark B.Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet1989; i: 117-120.
11.
Buchanan RB , Blamey RW, Durrant KR et al. A randomised comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol1986; 4: 1326-30.
12.
Ingle JN, Krook JE, Green SJ et al. Randomised trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol1986; 4: 178-85.
13.
Nicholson RIZoladex and tamoxifen versus Zoladex alone in pre and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol1990; 37: 989-95.
14.
Harris AL, Carmichael J., Cantwell Bmj, Dowsett M.Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer . Br J Cancer1989; 59: 97-99.
15.
Waxman J.A new understanding of the hormonal regulation of endocrine dependent cancer . Br Med Bull1991; Jan 47: 197-208.
16.
Cocconi G., Bisagni G., Ceci G. et al. Low dose aminoglutethimide with and without hydrocortisone replacement as first-line endocrine treatment in advanced breast cancer: a prospective randomised trial of the Italian Oncology Group for clinical research. J Clin Oncol.1992; 10: 984-89.
17.
Ribeiro GGA clinical trial to compare the use of tamoxifen vs stilboestrol in the treatment of postmenopausal women with advanced breast cancer. Rev Endocrinol Relate Cancer1981; 9 (suppl): 409.
18.
Rubens RD, Tinson CL, Cloeman RE et al.. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer1988 ; 58: 626-30.
19.
Heath DA, Hypercalcaemia of malignancy. Palliative Med1989; 3: 1-11.
20.
McLeod DG, Crawford ED, Blumenstein BA, Eisenberger MA, Dorr FAControversies in the treatment of metastatic prostate cancer. Cancer1992; 70: 324-328.
21.
Gallagher CJThe role of Gonadotrophin-Releasing Hormone analogues in the management of prostate cancer [Editorial]. Clin Oncol1992; 4: 137-38.
22.
Perez CA, Fair WR, Ihde DCCarcinoma of the prostate. In: DeVita VT Jr, Hellman H, Rosenberg SA eds. Cancer: principles and practice of oncology , third edition. Philadelphia: JB Lippincott, 1989: 1023-58.
23.
Eaton CL, Griffiths K.The role of endocrine therapy in prostatic cancer. Bailliere's Clin Endocrinol Metab1990; 4.: 85-96.
24.
Nesbit RM, Baum WCEndocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. JAMA1950; 143: 1317-20.
25.
Lepor H., Ross A., Walsh PCThe influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol1982; 128: 335-40.
26.
Byar DP, Corle DKHormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. In: NCI monographs , no. 7. Washington: DCGovernment Printing Office, 1988: 165-70.
27.
Pavone-Macaluso M, De VoogtHJGV. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised phase III trial of the EORTC urological group. J Urol1986; 136: 624-31.
28.
TheLeuprolide Study group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med1984; 311: 1281-86.
29.
Parmar H., Phillips RH, Lightman SL et al. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet1985; 2: 1201-1205.
30.
Moffat Lef.Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol1990; 18 (suppl 3):26-27.
31.
Cassileth BR , Soloway MS, Vogelzang NJ et al. Patients' choice of treatment in staged prostate cancer. Urology1989; 33 (suppl 5): 57-62.
32.
Drug and Therapeutics Bulletin. Gonadotrophin releasing hormone analogues for advanced prostate cancer, volume 30, No 17. 17 August 1992.
33.
Waxman J., Saini A.The current status of scientific research and hormonal treatments for carcinoma of the prostate [Editorial]. BrJ Cancer1991 ; 64: 419-21.
34.
Lund F., Rasmussen F.Flutamide versus stilboestrol in themanagement of advanced prostatic cancer . Br J Urol1988; 61: 140-42.
35.
Delacre Kpj , Van Thillo EL.Flutamide monotherapy as primary treatment in advanced prostate carcinoma. Semin Oncol1991; 5 (suppl 6): 13-18.
36.
Crawford EDHormonal therapy of prostatic cancer. Defining the challenge. Cancer1990; 66 (suppl): 1035-38.
Johnson DE, Babaian RJ, von Eschenbach AC, Wishnow KI, Tenney D.Ketoconazole therapy for hormonally refractive metastatic prostate cancer . Urology1988; 31: 132-34.
39.
Worgul TJ, Santen RJ, Samojlik et al. Clinical and biochemical effect of aminogutethimide in the treatment of advanced prostatic carcinoma. J Urol1983 ; 129: 51-55.
40.
Plowman PN, Perry LA, Chard T.Androgen suppression by hydrocortisone without aminoglutethimide in orchidectomised men with prostate cancer. Br J Urol1987;59:255-57.
41.
Tannock I., Gospodarowicz M., Meakin W. et al. Treatment of metastatic prostatic cancer with low-dose prednisolone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol1989;7:590-97.
42.
Ballentine Carter H., Isaacs JTOverview of hormonal therapy for prostate cancer. Progress Clin Biol Res1990; 350: 129-40.
43.
Labrie F., Dupont A., Cusan L. et al. Combination therapy with flutamide and castration (LHRH agonists or orchidectomy) in previously untreated patients with clinical stage D2 prostatic cancer: today's therapy of choice. J Steroid Biochem1988; 30: 1-6, 107.
44.
Crawford ED , Eisenberger MA, Meleod DGA controlled trial of Leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med1989; 321: 419-24.
45.
Di Silverio F., Serio M., Eramo GD, Sciarra F.Zoladex vs Zoladex plus cyproterone acetate in the treatment of advanced prostate cancer: a multicenter Italian Study . Eur Urol1990; 18 (suppl 3): 54-61.
46.
Twycross R.Corticosteroids in advanced cancer. Br Med J1992; 305: 969-70.
47.
Tannock IFIs there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?J Clin Oncol1985; 3: 1013-21.
48.
Ventafridda V. , Sbanotto A., DeConno F.Pain in prostatic cancer. Palliative Med1990; 4: 173-84.
Kneale Blg.Adjunctive and therapeutic progetins in endometrial cancer. Clin Obstet Gynaecol1986; 13: 789-809.
51.
Hoskins WJ, Perez C., Young RCGynecologic tumours. In: Devita VT Jr, Hellman H, Rosenberf SA eds. Cancer: principles and practice of oncology , third edition. Philadelphia: JB Lippincott, 1099-161.
52.
Ehrlich CE, Young Pcm, Stehman FB, Sutton GP, Alford WMSteroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol1988; 158: 796-807.
53.
Coulter C., Mason P.Cervix and endometrium. In: Sikora K, Halnan KE eds. Treatment of cancer, second edition. London: Chapman & Hall , 1990: 579-96.
54.
Satyaswaroop PG, Mortel R.Hormonal treatment of endometrial carcinoma: overview and new development in biology. J Steroid Biochem Molec Biol1990; 37:997-1001.
55.
Lind MJ, Cantwell Bmj, Millward MJ et al. A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer1992; 65: 621-23.
56.
Blackledge G., Varma R.Chemotherapy, hormonal therapy, and steroid receptors in gynaecology cancer. Curr Op Oncol1990; 2: 881-84.
Malik Sta, Slevin MLMedroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary - a new therapeutic approach?Br J Cancer1991; 63: 410-11.
59.
Isaacs R., Forgeson G., Allan S.Progestogens for granulosa cell tumours of the ovary. Br J Cancer1992; 65: 140.
60.
Hatch KD, Beecham JB, Blessing JA, Creasman WTResponsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer1991; 68: 269-71.
